Pharma & Biotech

Showing 1–12 of 28 results

Equity Medtronic

Medtronic plc (MDT) (Q3FY24) – Cardiac ablation solutions business faces market challenges

The challenges faced by MDT in RAS market include integrating AI and automation in surgery, which raises many ethical challenges that warrant careful consideration.
Merck & Co
Merck’s oncology business, spearheaded by its flagship product KEYTRUDA, showcases the company’s proficiency in developing and marketing innovative and commercially successful therapies.
Zoetis
In clinical studies, Solensia has shown that a total of 76% of cat owners reported sustained improvement in signs of pain when their cats were treated with Solensia.
Teva
Teva is strategically positioning itself to introduce five biosimilars within the next four years, targeting key medications like Humira and Stelara.
Boston Scientific
Boston Scientific reported excellent results for 2023, with one of the strongest years in the company’s history. The company’s total operational sales grew by 15% in Q4 2023 and 13% for the full year, exceeding its financial goals.
Novartis
The promising results for Scemblix and Iptacopan, in particular, represent significant advancements in their respective therapeutic areas, potentially opening up new revenue streams and strengthening Novartis’ market position.
Abbott Laboratories
Abbott Laboratories has built a strong brand reputation and customer loyalty across its diverse product portfolio. In the nutrition segment, the company regained its market leadership position in the U.S. infant formula business, reflecting the trust and confidence of its users and customers in Abbott’s products.
Pfizer
The Prevnar franchise, a significant revenue contributor for Pfizer, faced several challenges. In the U.S. adult market, the catch-up opportunity for Prevnar 20 has been largely exhausted, with a diminishing patient pool and increasing competition expected.
Thermo Fisher Scientific
Thermo Fisher Scientific, a leading player in the bioproduction market, faced challenges amidst market volatility in 2023. Despite this, the company remains optimistic about its long-term growth potential.
UnitedHealth Group
UnitedHealth Group continues to invest heavily in digital capabilities and artificial intelligence (AI) to enhance customer experiences, improve operational efficiencies, and drive productivity gains.
Regeneron
Regeneron Pharmaceuticals is facing heightened competition in the retinal disease and dermatology sectors, with the introduction of biosimilar alternatives like Lucentis and brolucizumab in the retinal category, and new JAK inhibitors challenging Dupixent in atopic dermatitis.
Johnson & Johnson
Johnson & Johnson faces competitive pressures and the loss of exclusivity for several key products, which could impact future revenue growth.